Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

GILD

Gilead Sciences, Inc

Feb 11 • 04:00PM ET

155.80

+8.57 5.82 %

Healthcare • Drug Manufacturers - General • USA • NASD

Feb 11, 10:45 AMGilead posts a Q4 2025 beat (revenue up 5% to $7.9B; non-GAAP EPS $1.86), beats 2025 guidance and raises its 2026 outlook on HIV strength despite a cell-therapy drag, and lifts its dividend 3.8% to $0.82 starting Q1 2026. Shares rebound from an early ~3% drop to record highs as at least 11 analysts, including Scotiabank, raise price targets following the results.

Peers: ABBV BMY MRK PFE AMGN JNJ LLY VRTX REGN BIIB

| Held by: VTI QQQ VOO IVV SPY VTV XLV IBB QQQM VYM

Scroll to Statements

Index	NDX, S&P 500	P/E	22.98	EPS (ttm)	6.78	Insider Own	0.23%	Shs Outstand	1.24B	Perf Week	6.54%
Market Cap	193.30B	Forward P/E	16.16	EPS next Y	9.64	Insider Trans	-13.48%	Shs Float	1.24B	Perf Month	27.08%
Enterprise Value	207.55B	PEG	1.87	EPS next Q	1.88	Inst Own	89.40%	Short Float	1.91%	Perf Quarter	31.87%
Income	8.51B	P/S	6.57	EPS this Y	7.20%	Inst Trans	0.65%	Short Ratio	3.21	Perf Half Y	29.81%
Sales	29.42B	P/B	8.55	EPS next Y	10.36%	ROA	14.42%	Short Interest	23.68M	Perf YTD	26.93%
Book/sh	18.23	P/C	18.23	EPS next 5Y	8.65%	ROE	40.57%	52W High	153.13 1.74%	Perf Year	62.06%
Cash/sh	8.55	P/FCF	21.10	EPS past 3/5Y	23.05% 133.63%	ROIC	19.48%	52W Low	93.37 66.86%	Perf 3Y	79.70%
Dividend Est.	3.47 (2.23%)	EV/EBITDA	14.72	Sales past 3/5Y	2.82% 3.62%	Gross Margin	87.83%	Volatility	3.60% 3.07%	Perf 5Y	132.82%
Dividend TTM	3.16 (2.03%)	EV/Sales	7.06	EPS Y/Y TTM	1682.88%	Oper. Margin	40.08%	ATR (14)	4.18	Perf 10Y	78.34%
Dividend Ex-Date	Mar 13, 2026	Quick Ratio	1.31	Sales Y/Y TTM	2.41%	Profit Margin	28.93%	RSI (14)	75.49	Recom	1.70
Dividend Gr. 3/5Y	2.67% 3.04%	Current Ratio	1.68	EPS Q/Q	22.86%	SMA20	12.11%	Beta	0.38	Target Price	153.12
Payout	46.61%	Debt/Eq	1.10	Sales Q/Q	4.81%	SMA50	20.77%	Rel Volume	1.57	Prev Close	147.23
Employees	17600	LT Debt/Eq	0.98	Earnings	Feb 10 AMC	SMA200	32.64%	Avg Volume	7.38M	Price	155.80
IPO	Jan 22, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.76% 3.05%	Trades		Volume	11,433,950	Change	5.82%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-26	Reiterated	Needham	Buy	$140 → $170
Jan-07-26	Resumed	UBS	Buy	$145
Nov-24-25	Resumed	Truist	Buy	$140
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$140
Aug-19-25	Upgrade	Daiwa Securities	Neutral → Outperform	$128
Aug-08-25	Upgrade	Truist	Hold → Buy	$127
Jul-25-25	Upgrade	Needham	Hold → Buy	$133
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$125
Mar-04-25	Reiterated	Oppenheimer	Outperform	$115 → $132
Feb-18-25	Upgrade	Deutsche Bank	Hold → Buy	$120
Feb-13-25	Upgrade	DZ Bank	Hold → Buy	$108
Jan-10-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$87 → $113
Dec-10-24	Resumed	BofA Securities	Buy	$109
Nov-15-24	Initiated	Wolfe Research	Outperform	$110
Nov-14-24	Initiated	Citigroup	Buy	$125
Nov-08-24	Downgrade	Maxim Group	Buy → Hold
Oct-21-24	Upgrade	Leerink Partners	Market Perform → Outperform	$74 → $96
Oct-17-24	Initiated	Bernstein	Outperform	$105
Oct-07-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$78 → $100
Jul-08-24	Upgrade	Raymond James	Mkt Perform → Outperform	$93

Show Previous Ratings

Feb-11-26 07:24PM	Gilead Sciences Stock Spikes After Q4 Results: Time to Buy? (Zacks) +5.82%
04:05PM	Gilead Bounds Higher As Analysts Debate The Future Of Its Potential HIV Blockbuster (Investor's Business Daily)
02:23PM	Software Slump Resumes, Bitcoin Plunges To 66,000: What's Moving Markets Wednesday? (Benzinga)
11:23AM	Stocks Turn Mixed as Software Stocks Slide (Barchart)
11:05AM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
10:40AM	Loading…
10:40AM	Gilead Sciences Stock Surges to Record Highs Amid Bull Notes (Schaeffer's Research)
10:15AM	GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales (Zacks)
08:11AM	Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target (Pharmaceutical Technology)
07:41AM	These Stocks Are Todays Movers: Moderna, Robinhood, Shopify, Kraft Heinz, Cloudflare, Humana, Lyft, Mattel, Beta Tech, and More (Barrons.com)
06:01AM	These Stocks Are Today's Movers: Moderna, Robinhood, Cloudflare, Lyft, Mattel, Beta Technologies, Gilead, and More (Barrons.com)
12:31AM	GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook (StockStory)
12:03AM	Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ... (GuruFocus.com)
Feb-10-26 06:30PM	Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:19PM	Gilead Sciences Q4 Earnings Call Highlights (MarketBeat)
05:56PM	Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance (Benzinga)
05:10PM	Loading…
05:10PM	Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:51PM	Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. (Barrons.com)
04:39PM	Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products (The Wall Street Journal)
04:17PM	Gilead Sciences's (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates (StockStory)
04:13PM	Gilead: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Will Gilead's Solid Fourth Quarter Be Enough To Shake Off Its Light Outlook? (Investor's Business Daily)
04:02PM	Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend (Business Wire)
04:01PM	Gilead's Earnings Surprise. HIV Drug Sales Were Strong. (Barrons.com)
04:01PM	Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
12:37PM	Stock Market Today, Feb: 10: Dow hits intraday record after retail sales disappoint (TheStreet)
07:20AM	Stocks to Watch Tuesday: Coca-Cola, Onsemi, Spotify (The Wall Street Journal)
03:14AM	Cisco Earnings, Jobs Report, CPI Data: What to Watch This Week (The Wall Street Journal)
Feb-09-26 07:12PM	2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD (Zacks)
11:38AM	Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? (Zacks)
11:30AM	Robinhood, AppLovin, Rivian and More Stocks With Earnings This Week (Benzinga)
06:23AM	Loading…
06:23AM	Stocks Set for Muted Open as Bond Yields Climb, Key U.S. Economic Data Awaited (Barchart)
06:00AM	Lilly bets again on China drugs; Roche showcases MS data (BioPharma Dive)
02:30AM	Jobs Report, CPI Data: What to Watch This Week (The Wall Street Journal)
Feb-08-26 10:03PM	Gilead Sciences (GILD) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
Feb-06-26 06:45PM	Jobs Report, CPI Data: What to Watch Next Week (The Wall Street Journal)
11:44AM	Is Gilead Sciences (GILD) a 'Buy' Ahead of Its Upcoming Earnings Announcement? (Zacks)
08:30AM	FDA Approves Label Update for Kite's Yescarta for Relapsed/Refractory Primary Central Nervous System Lymphoma (Business Wire)
Feb-05-26 03:05PM	This Overlooked Biotech Giant Could Surprise Investors This Quarter (Barchart)
10:00AM	Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
09:15AM	Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
09:15AM	Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings? (Zacks)
Feb-04-26 05:50PM	Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts (Zacks)
Feb-03-26 10:00AM	Earnings Preview: Gilead Sciences (GILD) Q4 Earnings Expected to Decline (Zacks)
09:27AM	Here's Why Gilead Sciences Stock Surged 21% in a Month (Zacks)
Feb-02-26 07:29PM	Gilead Sciences, Inc. (GILD): A Bull Case Theory (Insider Monkey)
10:24AM	Implied Volatility Surging for Gilead Sciences Stock Options (Zacks)
Feb-01-26 12:54PM	Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating (Insider Monkey)
Jan-31-26 12:35PM	UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook (Insider Monkey)
Jan-30-26 08:08PM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
06:00PM	Gilead Sciences (GILD) Advances While Market Declines: Some Information for Investors (Zacks)
11:15AM	Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season (Investor's Business Daily)
Jan-29-26 11:37PM	3 Cash-Producing Stocks with Warning Signs (StockStory)
08:23AM	Are Wall Street Analysts Predicting Gilead Sciences Stock Will Climb or Sink? (Barchart)
Jan-28-26 12:47PM	Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. (Barrons.com)
09:48AM	Some of Pharma's Biggest Brands Face a New Reality (GuruFocus.com)
09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:20AM	Gilead price target raised to $145 from $140 at Truist (TipRanks)
07:48AM	CMS selects next batch of 15 high-cost medicines for third negotiation cycle (Pharmaceutical Technology)
05:51AM	Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle (Benzinga)
Jan-27-26 04:05PM	Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026 (Business Wire)
Jan-22-26 06:00PM	Why Gilead Sciences (GILD) Outpaced the Stock Market Today (Zacks)
Jan-21-26 05:00PM	New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy Plus Keytruda as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer (Business Wire)
Jan-19-26 08:15AM	Gilead Sciences Earnings Preview: What to Expect (Barchart)
Jan-14-26 09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jan-13-26 01:01PM	Ex-Lazard Banker Charged in Insider Trading Case Tied to Health-Care Deals (GuruFocus.com)
07:47AM	JPM26: HIV pipeline dosing optionality gives Gilead advantage (Pharmaceutical Technology)
Jan-12-26 06:00PM	Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
10:07AM	Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history (CNBC TV)
04:32AM	UBS and Citi Go Bullish on Gilead Sciences (GILD) (Insider Monkey)
Jan-10-26 09:25AM	Gilead price target raised to $154 from $144 at BofA (TipRanks)
Jan-09-26 07:23AM	J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts (Pharmaceutical Technology)
Jan-07-26 09:50AM	Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock (Zacks)
Jan-06-26 07:00AM	OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD Delivery Technology to Gilead's Drug Candidate (Business Wire)
05:30AM	Big Pharma Has More Going for It Than Obesity Drugs (The Wall Street Journal)
Jan-05-26 11:01PM	Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
06:00PM	Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors (Zacks)
01:52PM	Biotech and Pharma Stocks Tumble as Investors Race into Energy (Barrons.com)
01:45PM	KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? (Zacks)
Jan-02-26 01:45PM	3 Cash-Flow Machines Investors May Want Heading Into 2026 (MarketBeat)
Dec-31-25 11:25AM	Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026 (Insider Monkey)
Dec-30-25 05:50PM	Why Gilead Sciences (GILD) Dipped More Than Broader Market Today (Zacks)
05:42PM	Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs (Insider Monkey)
04:31PM	Stocks Fall Slightly in Thin Holiday Trade (Barchart)
11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-29-25 11:59PM	Is Gilead Sciences (GILD) An Affordable Healthcare Stocks to Invest In? (Insider Monkey)
Dec-26-25 04:16AM	Gilead Sciences to acquire Repares RP-3467 (Pharmaceutical Technology)
Dec-23-25 10:45AM	GILD Exercises Option to License Assembly Bio's Herpes Programs (Zacks)
Dec-22-25 04:05PM	Gilead Sciences to Present at Upcoming Investor Conference (Business Wire)
11:39AM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
08:27AM	Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals (Zacks)
08:00AM	Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes (Business Wire)
Dec-19-25 05:40PM	Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump (Investor's Business Daily)
04:46PM	Trump reaches deal with 9 drug companies to lower prices (Yahoo Finance Video)
04:30PM	Nine Drugmakers Strike Deals With Trump, With More to Come (Bloomberg)
03:16PM	Why Gilead Sciences (GILD) Stock Is Up Today (StockStory)
02:50PM	More Big Drugmakers Reach Pricing Deals With White House (The Wall Street Journal)
02:21PM	Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans (Business Wire)
10:45AM	Trump to announce new drug-pricing deals later today (MarketWatch)
08:12AM	Will GILD's Strong HIV Portfolio Reap Rewards in 2026? (Zacks)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Day Daniel Patrick	Chairman & CEO	Feb 05 '26	Option Exercise	66.01	115,640	7,633,396	729,552	Feb 06 04:22 PM
O'Day Daniel Patrick	Chairman & CEO	Feb 05 '26	Sale	150.00	115,640	17,346,000	613,912	Feb 06 04:22 PM
DANIEL O'DAY	Officer	Feb 05 '26	Proposed Sale	150.00	115,640	17,346,000		Feb 05 04:05 PM
O'Day Daniel Patrick	Chairman & CEO	Jan 28 '26	Sale	139.89	10,000	1,398,911	556,698	Jan 29 05:23 PM
DANIEL O'DAY	Officer	Jan 28 '26	Proposed Sale	139.89	10,000	1,398,911		Jan 28 05:02 PM
O'Day Daniel Patrick	Chairman & CEO	Jan 23 '26	Option Exercise	66.01	115,640	7,633,396	682,338	Jan 26 07:29 PM
O'Day Daniel Patrick	Chairman & CEO	Jan 23 '26	Sale	135.00	115,640	15,611,400	566,698	Jan 26 07:29 PM
DANIEL O'DAY	Officer	Jan 23 '26	Proposed Sale	135.00	115,640	15,611,400		Jan 23 04:03 PM
DEBORAH TELMAN	Officer	Jan 22 '26	Proposed Sale	129.11	29,215	3,771,949		Jan 22 04:32 PM
Bluestone Jeffrey	Director	Jan 20 '26	Option Exercise	67.45	5,000	337,250	13,920	Jan 21 04:26 PM
Bluestone Jeffrey	Director	Jan 20 '26	Sale	123.50	5,000	617,500	8,920	Jan 21 04:26 PM
JEFFREY BLUESTONE	Director	Jan 20 '26	Proposed Sale	123.50	5,000	617,500		Jan 20 04:01 PM
Dickinson Andrew D	Chief Financial Officer	Jan 15 '26	Sale	124.31	3,000	372,930	150,503	Jan 16 06:18 PM
Mercier Johanna	Chief Commercial Officer	Jan 15 '26	Sale	124.31	3,000	372,930	103,221	Jan 16 06:10 PM
JOHANNA MERCIER	Officer	Jan 15 '26	Proposed Sale	124.31	3,000	372,930		Jan 15 04:02 PM
ANDREW DICKINSON	Officer	Jan 15 '26	Proposed Sale	124.31	3,000	372,930		Jan 15 04:01 PM
O'Day Daniel Patrick	Chairman & CEO	Dec 29 '25	Sale	124.83	10,000	1,248,272	566,698	Dec 30 04:23 PM
DANIEL O'DAY	Officer	Dec 29 '25	Proposed Sale	124.83	10,000	1,248,272		Dec 29 04:04 PM
Dickinson Andrew D	Chief Financial Officer	Dec 15 '25	Sale	122.00	3,000	366,000	153,503	Dec 16 06:31 PM
Mercier Johanna	Chief Commercial Officer	Dec 15 '25	Sale	122.00	3,000	366,000	106,221	Dec 16 06:12 PM
JOHANNA MERCIER	Officer	Dec 15 '25	Proposed Sale	122.00	3,000	366,000		Dec 15 04:04 PM
ANDREW DICKINSON	Officer	Dec 15 '25	Proposed Sale	122.00	3,000	366,000		Dec 15 04:04 PM
Bluestone Jeffrey	Director	Nov 28 '25	Option Exercise	64.92	5,000	324,600	13,920	Dec 01 06:11 PM
Bluestone Jeffrey	Director	Nov 28 '25	Sale	125.08	5,000	625,400	8,920	Dec 01 06:11 PM
Kramer Kelly A.	Director	Nov 26 '25	Option Exercise	81.00	2,806	227,286	4,145	Dec 01 04:54 PM
Kramer Kelly A.	Director	Nov 28 '25	Option Exercise	81.00	2,805	227,205	4,144	Dec 01 04:54 PM
Kramer Kelly A.	Director	Nov 26 '25	Sale	127.11	2,806	356,671	1,339	Dec 01 04:54 PM
Kramer Kelly A.	Director	Nov 28 '25	Sale	127.10	2,805	356,516	1,339	Dec 01 04:54 PM
O'Day Daniel Patrick	Chairman & CEO	Nov 28 '25	Sale	126.54	10,000	1,265,444	571,203	Dec 01 04:50 PM
DANIEL O'DAY	Officer	Nov 28 '25	Proposed Sale	126.54	10,000	1,265,444		Nov 28 01:05 PM
JEFFREY BLUESTONE	Director	Nov 28 '25	Proposed Sale	125.08	5,000	625,400		Nov 28 01:02 PM
KELLY KRAMER	Director	Nov 26 '25	Proposed Sale	127.12	5,611	713,270		Nov 26 04:16 PM
Dickinson Andrew D	Chief Financial Officer	Nov 17 '25	Sale	125.23	2,500	313,075	154,555	Nov 18 07:00 PM
Mercier Johanna	Chief Commercial Officer	Nov 17 '25	Option Exercise	66.64	25,000	1,666,000	135,193	Nov 18 06:51 PM
Mercier Johanna	Chief Commercial Officer	Nov 17 '25	Sale	125.86	28,000	3,524,173	107,193	Nov 18 06:51 PM
JOHANNA MERCIER	Officer	Nov 17 '25	Proposed Sale	125.86	28,000	3,524,173		Nov 17 04:06 PM
ANDREW DICKINSON	Officer	Nov 17 '25	Proposed Sale	125.23	2,500	313,075		Nov 17 04:05 PM
Telman Deborah H	EVP, Corporate Affairs & GC	Nov 12 '25	Option Exercise	65.35	53,646	3,505,885	79,641	Nov 13 07:36 PM
Telman Deborah H	EVP, Corporate Affairs & GC	Nov 12 '25	Sale	122.85	53,646	6,590,487	43,676	Nov 13 07:36 PM
DIANE E WILFONG	Officer	Nov 13 '25	Proposed Sale	127.02	3,500	444,556		Nov 13 05:07 PM
DEBORAH TELMAN	Officer	Nov 12 '25	Proposed Sale	122.56	55,646	6,819,974		Nov 12 04:36 PM
O'Day Daniel Patrick	Chairman & CEO	Oct 28 '25	Sale	119.39	10,000	1,193,926	581,203	Oct 29 04:14 PM
DANIEL ODAY	Officer	Oct 28 '25	Proposed Sale	119.39	10,000	1,193,926		Oct 28 05:47 PM
Dickinson Andrew D	Chief Financial Officer	Oct 15 '25	Sale	118.08	2,500	295,200	157,055	Oct 16 09:35 PM
Mercier Johanna	Chief Commercial Officer	Oct 15 '25	Sale	118.08	3,000	354,240	110,193	Oct 16 09:28 PM
ANDREW DICKINSON	Officer	Oct 15 '25	Proposed Sale	118.08	2,500	295,200		Oct 15 04:05 PM
JOHANNA MERCIER	Officer	Oct 15 '25	Proposed Sale	118.08	3,000	354,240		Oct 15 04:03 PM
O'Day Daniel Patrick	Chairman & CEO	Sep 29 '25	Sale	111.66	10,000	1,116,564	591,203	Sep 30 04:57 PM
DANIEL O'DAY	Officer	Sep 29 '25	Proposed Sale	111.66	10,000	1,116,564		Sep 29 04:09 PM
Mercier Johanna	Chief Commercial Officer	Sep 15 '25	Sale	113.57	3,000	340,710	113,193	Sep 16 05:16 PM
Dickinson Andrew D	Chief Financial Officer	Sep 15 '25	Sale	113.57	2,500	283,925	159,555	Sep 16 05:12 PM
ANDREW DICKINSON	Officer	Sep 15 '25	Proposed Sale	113.57	2,500	283,925		Sep 15 04:38 PM
JOHANNA MERCIER	Officer	Sep 15 '25	Proposed Sale	113.57	3,000	340,710		Sep 15 04:04 PM
O'Day Daniel Patrick	Chairman & CEO	Aug 28 '25	Sale	113.63	10,000	1,136,300	595,725	Aug 29 04:16 PM
DANIEL O'DAY	Officer	Aug 28 '25	Proposed Sale	113.63	10,000	1,136,300		Aug 28 04:47 PM
Mercier Johanna	Chief Commercial Officer	Aug 15 '25	Option Exercise	66.64	25,000	1,666,000	128,968	Aug 18 08:56 PM
Mercier Johanna	Chief Commercial Officer	Aug 15 '25	Sale	118.53	28,000	3,318,927	114,168	Aug 18 08:56 PM
Dickinson Andrew D	Chief Financial Officer	Aug 15 '25	Sale	118.53	2,500	296,325	160,110	Aug 18 07:34 PM
ANDREW DICKINSON	Officer	Aug 15 '25	Proposed Sale	118.53	2,500	296,325		Aug 15 04:23 PM
JOHANNA MERCIER	Officer	Aug 15 '25	Proposed Sale	118.53	28,000	3,318,925		Aug 15 04:02 PM
O'Day Daniel Patrick	Chairman & CEO	Jul 28 '25	Sale	113.94	10,000	1,139,370	605,725	Jul 29 04:54 PM
DANIEL ODAY	Officer	Jul 28 '25	Proposed Sale	113.94	10,000	1,139,369		Jul 28 04:36 PM
Mercier Johanna	Chief Commercial Officer	Jul 15 '25	Sale	111.03	3,000	333,090	117,168	Jul 16 05:45 PM
Dickinson Andrew D	Chief Financial Officer	Jul 15 '25	Sale	111.03	2,500	277,575	162,610	Jul 16 05:41 PM
JOHANNA MERCIER	Officer	Jul 15 '25	Proposed Sale	111.03	3,000	333,090		Jul 15 04:36 PM
ANDREW DICKINSON	Officer	Jul 15 '25	Proposed Sale	111.03	2,500	277,575		Jul 15 04:03 PM
Bluestone Jeffrey	Director	Jul 14 '25	Option Exercise	67.45	5,000	337,250	13,920	Jul 15 03:59 PM
Bluestone Jeffrey	Director	Jul 14 '25	Sale	109.74	5,000	548,700	8,920	Jul 15 03:59 PM
JEFFREY BLUESTONE	Director	Jul 14 '25	Proposed Sale	109.74	5,000	548,700		Jul 14 04:01 PM
O'Day Daniel Patrick	Chairman & CEO	Jun 30 '25	Sale	110.45	10,000	1,104,484	615,725	Jul 01 06:02 PM
DANIEL O'DAY	Officer	Jun 30 '25	Proposed Sale	110.45	10,000	1,104,483		Jun 30 04:05 PM
Dickinson Andrew D	Chief Financial Officer	Jun 16 '25	Sale	110.17	2,500	275,425	165,110	Jun 17 06:08 PM
Mercier Johanna	Chief Commercial Officer	Jun 16 '25	Sale	110.17	3,000	330,510	120,168	Jun 17 06:04 PM
JOHANNA MERCIER	Officer	Jun 16 '25	Proposed Sale	110.17	3,000	330,510		Jun 16 04:05 PM
ANDREW DICKINSON	Officer	Jun 16 '25	Proposed Sale	110.17	2,500	275,425		Jun 16 04:01 PM
O'Day Daniel Patrick	Chairman & CEO	May 30 '25	Sale	110.42	10,000	1,104,193	620,268	Jun 02 08:55 PM
DANIEL O'DAY	Officer	May 30 '25	Proposed Sale	110.42	10,000	1,104,192		May 30 04:16 PM
Mercier Johanna	Chief Commercial Officer	May 22 '25	Option Exercise	66.64	25,000	1,666,000	136,652	May 23 03:16 PM
Mercier Johanna	Chief Commercial Officer	May 22 '25	Sale	107.52	28,000	3,010,564	121,152	May 23 03:16 PM
JOHANNA MERCIER	Officer	May 22 '25	Proposed Sale	107.52	28,000	3,010,562		May 22 04:01 PM
Dickinson Andrew D	Chief Financial Officer	May 15 '25	Sale	99.82	2,500	249,550	165,674	May 16 04:34 PM
ANDREW DICKINSON	Officer	May 15 '25	Proposed Sale	99.82	2,500	249,550		May 15 04:03 PM
Dickinson Andrew D	Chief Financial Officer	Apr 15 '25	Sale	106.40	2,500	266,000	168,174	Apr 16 03:22 PM
ANDREW DICKINSON	Officer	Apr 15 '25	Proposed Sale	106.40	2,500	266,000		Apr 15 04:04 PM
Dickinson Andrew D	Chief Financial Officer	Mar 17 '25	Sale	110.53	2,500	276,325	170,674	Mar 18 04:37 PM
ANDREW DICKINSON	Officer	Mar 17 '25	Proposed Sale	110.53	2,500	276,325		Mar 17 04:16 PM
Dickinson Andrew D	Chief Financial Officer	Mar 10 '25	Option Exercise	63.91	17,929	1,145,842	186,990	Mar 12 06:41 PM
Dickinson Andrew D	Chief Financial Officer	Mar 10 '25	Sale	118.17	17,929	2,118,696	169,061	Mar 12 06:41 PM
ANDREW DICKINSON	Officer	Mar 10 '25	Proposed Sale	118.17	17,929	2,118,695		Mar 10 04:02 PM
MERDAD V PARSEY	Officer	Mar 03 '25	Proposed Sale	115.70	21,910	2,534,913		Mar 03 04:26 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 18 '25	Buy	11.00	1,363,636	14,999,996	31,424,760	Feb 20 07:42 PM
Dickinson Andrew D	Chief Financial Officer	Feb 18 '25	Sale	104.09	2,500	260,225	169,061	Feb 19 04:43 PM
ANDREW DICKINSON	Officer	Feb 18 '25	Proposed Sale	104.09	2,500	260,225		Feb 18 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GILD

Gilead Sciences, Inc

Upgrade your FINVIZ experience